- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03971006
Immune Alveolar Alterations During Pneumonia-Associated Acute Respiratory Distress Syndrome (PICARD2)
Sepsis is a dysregulated host response to severe life-threatening infections, leading to organ failure and death in up to 40% of patients with septic shock. Pulmonary infections are the main cause of community-acquired sepsis and frequently lead to the development of acute respiratory distress syndrome(ARDS). Features of immunosuppression, including diminished cell surface monocyte human leukocyte antigen DR (mHLA-DR) expression, are strongly associated with hospital mortality. Such decrease in HLA-DR expression on antigen-presenting cells has been associated with impairment of microbial antigens to Tcells. Septic patients also show elevated expression of inhibitory receptors associated with cell exhaustion.. Yet, biochemical, flow cytometric and immunohistochemical findings consistent with immunosuppression have been observed in lungs and spleen of patients died of sepsis and multiple organ failure, demonstrating the relevance of studying these defects directly in organ tissues. A novel approach aimed to characterize the role and prognostic value of alveolar biomarkers measured directly in the injured lungs is warranted and supported by: -disappointing results of previous clinical trials attempting to restore the level of biomarkers measured on circulating cells; -evidences of regional immunosuppression in lungs of ARDS patients; -lung is the main site of hospital-acquired infections with a prevalence of ventilator-associated pneumonia in 30% over the course of Intensive Care Unit(ICU) stay in ARDS patients.
Investigators speculate that biomarkers measured on alveolar leukocytes (AL) surface, are important predictors of outcome and potential therapeutic targets in ICU patients with pneumonia-associated ARDS.
Investigators aim to explore whether biomarkers measured directly on AL from patients with pneumonia-associated ARDS are associated to regional pulmonary immunosuppression using leukocyte functional tests; and predictors of outcomes.
Bronchoalveolar lavage fluid(BALF) and blood samples will be collected in ARDS patients. Leukocyte populations and cell membrane biomarkers will be quantified using flow cytometry. Leukocyte functional tests will be performed ex vivo on leukocytes collected from BALF and blood samples. Pharmacological interventions will be performed ex vivo.
This project aims to identify biomarkers associated with outcomes and potential therapeutic targets.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Nicolas DE PROST, Doctor
- Numero di telefono: 0033 01 49 81 23 94
- Email: nicolas.de-prost@aphp.fr
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age ≥ 18 years
- Affiliated to a social security system
- Patient informed and have given his non opposition verbally (trustworthy or a family member non opposition is required if the patient is unable to give his non opposition)
Groupe 1 :
- Patient with ARDS secondary to pneumonia defined by following criteria: Intubation and mechanical ventilation for less than 48 hours Lung infection evolving since less than 7 days Bilateral pulmonary radiological opacities compatible with edema pulmonary lesion PaO2 / FiO2 ratio ≤ 300 mmHg with a positive expiratory pressure level ≥ 5 cmH2O
- Absence of immunosuppression (No HIV infection, bone marrow or solid organ transplantation, post-chemotherapy aplasia, immunosuppressive therapy or corticosteroid therapy (>200 mg / day of hydrocortisone or equivalent in the 4 weeks prior to inclusion))
Group 2 - Patient with ARDS secondary to pneumonia defined by following criteria: Intubation and mechanical ventilation for less than 48 hours Lung infection evolving since less than 7 days Bilateral pulmonary radiological opacities compatible with edema pulmonary lesion PaO2 / FiO2 ratio ≤ 300 mmHg with a positive expiratory pressure level ≥ 5 cmH2O
- Previously known immunosuppression (patient with HIV, solid tumor, solid organ transplantation or under corticosteroids therapy since at least 4 weeks before inclusion)
Group 3
- LBA indicated in usual care
- Absence of ARDS
- Absence of evolutionary infection
- Absence of infiltrative lung disease
- Absence of immunosuppression (No HIV infection, bone marrow or solid organ transplantation, post-chemotherapy aplasia, immunosuppressive therapy, corticosteroid therapy (> 200 mg / day of hydrocortisone or equivalent in the 4 weeks prior to inclusion))
Exclusion Criteria:
- Chronic respiratory insufficiency treated by long-term oxygen therapy and / or long-term respiratory assistance
- Child-Pugh C cirrhosis
- Pulmonary fibrosis
- Active lymphoid and myeloid malignant hemopathies
- Neutropenia (neutrophils <1500 / mm3)
- Patient moribund the day of inclusion or having an IGS II score greater than 90
- Irreversible neurological pathology: cerebral involvement, encephalic death
- Decision to limit active therapies
- Deep hypoxemia (PaO2 / FiO2 <75 mmHg)
- Patient protected by law
- Pregnant or lactating woman
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Altro
- Prospettive temporali: Prospettiva
Coorti e interventi
Gruppo / Coorte |
---|
Immunocompetent ARDS patients
(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) and no immunosuppression (excluding patients with HIV infection, solid tumor or hematological malignancies, organ transplant or taking steroids since more than 4 weeks).
|
Immunosuppressed ARDS patients
(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) (Berlin definition (2)) and previously known immunosuppression (as listed above).
These patients will allow comparing the cell defects observed in the study population to those observed in immunosuppressed patients.
|
Controls
(n=10) Patients undergoing a bronchoscopy with Bronchoalveolar Liquid (BAL) as part of routine care but having neither ARDS nor active lung infection, infiltrating lung disease or immunosuppression.
These patients will allow quantifying normal levels of the studied biomarkers in the alveolar and blood compartments.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
HLA-DR expression level of alveolar monocytes at the early phase of infectious Acute Respiratory Distress Syndrome (ARDS)
Lasso di tempo: at day 1 to day 3
|
Measurement by flow cytometry phagocytosis and TNF-α synthesis of alveolar monocytes in immunocompetent patients, compared to immunocompromised patients
|
at day 1 to day 3
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Impact of the level of expression of PD-1 by alveolar CD8 + lymphocytes on their function during septic ARDS in immunocompetent and immunocompromised patients.
Lasso di tempo: at day 1 to day 3
|
Level of expression of PD-1 by alveolar CD8+ lymphocytes
|
at day 1 to day 3
|
Comparaison of the level of HLA-DR expression of alveolar monocytes between immunocompetent and immunosuppressed patients being managed for septic ARDS.
Lasso di tempo: at day 1 to day 3
|
Level of HLA-DR expression of alveolar monocytes
|
at day 1 to day 3
|
Link between the alveolar monocyte HLA-DR expression level and the prognosis of immunocompetent and immunosuppressed patients being managed for septic ARDS.
Lasso di tempo: day 28
|
Number of days without complication
|
day 28
|
Determine wether alveolar biomarkers (HLA-DR and PD-1) are potential candidates for immunomodulation
Lasso di tempo: at day 1 to day 3
|
To determine if the level of expression of HLA-DR and PD-1 can be modulated by pharmacological intervention
|
at day 1 to day 3
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Nicolas DE PROST, Assistance Publique Hôpitaux de Paris - CHU Henri Mondor - Créteil
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Infezioni
- Infezioni delle vie respiratorie
- Malattie delle vie respiratorie
- Disturbi respiratori
- Malattie polmonari
- Patologia
- Infante, neonato, malattie
- Lesione polmonare
- Infantile, prematuro, malattie
- Sindrome
- Polmonite
- Sindrome da stress respiratorio
- Sindrome da distress respiratorio, neonato
- Lesioni polmonari acute
Altri numeri di identificazione dello studio
- APHP 190092
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Sindrome da distress respiratorio acuto
-
Drägerwerk AG & Co. KGaAKKS DresdenCompletatoSindrome da distress respiratorio acuto | Ventilazione meccanica | Ventilazione monopolmone | ALI - Lesioni polmonari acute | Svezzamento dal ventilatoreGermania
-
Zhuan ZhangCompletatoBypass cardiopolmonare | Sindrome da distress respiratorio acuto | Ipossiemia | Lesioni polmonari, acuteCina
-
Wolfson Medical CenterSconosciutoSindrome da distress respiratorio acutoIsraele
-
Medical University of ViennaCompletatoMalattie delle vie respiratorie | Malattie polmonari | Ossigenazione extracorporea della membrana | Sindrome da stress respiratorio | Lesioni polmonari acute | Sindrome da distress respiratorio acuto | Lesioni polmonari, acuteAustria
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University of Sierra Leone; University of Bari; Doctors with Africa - CUAMM; Mahidol...CompletatoSindrome da distress respiratorio acuto | Malattia polmonare | Complicanza ostetrica | Lesioni polmonari, acuteSierra Leone
-
LUN WEI LIUChi Mei Medical HospitalCompletatoSindrome da distress respiratorio acuto | Lesioni polmonari, acuteTaiwan
-
Taichung Veterans General HospitalSconosciutoSindrome da distress respiratorio acutoTaiwan
-
University Hospital, BordeauxCompletatoSindrome da distress respiratorio acutoFrancia
-
Tanta UniversityReclutamentoDanno polmonare acuto/sindrome da distress respiratorio acuto (ARDS) | Sindrome da distress respiratorio, pediatricaEgitto
-
Aqualung Therapeutics Corp.Non ancora reclutamentoSindrome da distress respiratorio acuto (ARDS)